XML 50 R33.htm IDEA: XBRL DOCUMENT v3.23.2
Collaboration Agreements, License Agreement and Revenues - Astellas Agreements - Additional Information (Detail) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended
Apr. 30, 2006
Jun. 30, 2005
Jun. 30, 2023
Mar. 31, 2023
Jun. 30, 2022
Mar. 31, 2022
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Total revenue     $ 44,319,000   $ 29,806,000   $ 80,480,000 $ 90,633,000  
Deferred Revenue     7,490,000       7,490,000   $ 12,739,000
Drug Product Revenue, Net [Member]                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Total revenue     14,272,000   $ 1,093,000   16,381,000 $ 8,687,000  
Japan [Member]                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Transaction price, variable consideration from estimated future co-development billing             $ 0    
Japan [Member] | Drug Product Revenue, Net [Member]                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Total revenue     14,400,000 $ 1,700,000   $ 9,800,000      
Astellas Agreement [Member] | Japan [Member]                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Upfront, non-contingent and time-based payments received   $ 172,600,000              
Additional consideration based on net sales description             the low 20% range of the list price    
Aggregate consideration received excluding drug product revenue     105,100,000       $ 105,100,000    
Changes in revenue from changes to estimated variable consideration     0            
Astellas Agreement [Member] | Europe [Member]                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Upfront, non-contingent and time-based payments received $ 745,000,000.0                
Additional consideration based on net sales description             low 20% range    
Aggregate consideration received excluding drug product revenue     685,000,000.0       $ 685,000,000.0    
Transaction price, variable consideration from estimated future co-development billing             $ 2,700,000    
Percentage of joint development costs committed to fund 50.00%                
Transaction price and allocated to performance obligations           $ 25,000,000.0      
Changes in revenue from changes to estimated variable consideration     $ 0